Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SLDB, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| SGT-003 | Duchenne Muscular Dystrophy | Phase 3 · NCT07160634 | Recruiting |
| SGT-212 | Friedreich's Ataxia (FA) | Phase 1 · NCT07180355 | Recruiting |
| SGT-501 | Catecholaminergic Polymorphic Ventricular Tachycar | Phase 1 · NCT07148089 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SLDB holds $377.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $49.9M/quarter from operations, an estimated runway of 22.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 37 · Moderate
We believe that our cash, cash equivalents, and available-for-sale securities as of June 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into mid-2028.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SLDB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | Institution (13G, 5%+) | 12,046,579 | 11.23% | 2026-06-30 |
| Raymond Debbane | 5%+ holder (13G) | 10,066,682 | 9.39% | 2026-03-31 |
| Bain Capital Life Sciences Investors, LL | Institution (13F) | 9,808,819 | 9.15% | 2026-06-30 |
| BCLS II Investco, LP | 5%+ holder (13D) | 8,604,852 | 8.03% | 2026-03-06 |
| Siren, L.L.C. | Institution (13F) | 7,690,405 | 7.17% | 2026-06-30 |
| FMR LLC | Institution (13G, 5%+) | 6,875,957 | 6.41% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 6,419,730 | 5.99% | 2026-06-30 |
| Armistice Capital, LLC | Institution (13F) | 4,278,000 | 3.99% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 4,175,365 | 3.89% | 2026-06-30 |
| Jupiter Topco LLC | Institution (13F) | 4,043,605 | 3.77% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 4,009,922 | 3.74% | 2026-06-30 |
| Alexander Cumbo President and CEO, Director · +569,913 options |
Insider | 235,405 | 0.22% | 2026-02-13 |
Share count 107,225,238 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-07-02 filed 2026-07-07 |
SMITH IAN F |
Option exercise (M) | 3,440 | – | 138,145 |
| 2026-07-02 filed 2026-07-07 |
SMITH IAN F |
Option exercise (M) | 3,440 | – | – |
| 2026-06-10 filed 2026-06-11 |
Nagendran Sukumar |
Option award (A) | 77,500 | – | – |
| 2026-06-10 filed 2026-06-11 |
EDELMAN JOSEPH |
Option award (A) | 77,500 | – | – |
| 2026-06-10 filed 2026-06-11 |
SMITH IAN F |
Option award (A) | 77,500 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLDB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →